Design Limitless by Hyperlink InfoSystem Becomes a One-Stop Creative Partner for Branding, UI/UX, Motion Graphics & More
The service is built to cater to the evolving needs of startups, agencies, and enterprises through three purpose-driven subscription plans. The Essentials Package is best suited for startups or small teams looking for reliable creative support without the high cost of hiring in-house designers. It includes unlimited design requests, one active task at a time, access to a dedicated project manager, and a turnaround time of 1 to 2 business days per request - providing a solid foundation for early-stage brand development.
For businesses with more frequent or diverse design needs, the Standard Package offers increased flexibility and speed. It allows two active requests at a time and includes access to a broader range of creative services such as motion graphics, UI/UX design, and marketing collateral. This package is ideal for growing companies that need consistent output to fuel ongoing campaigns and product launches.
The Enterprise Package is built for high-growth companies, marketing agencies, and large organizations that require top-tier creative support at scale. With up to four active requests at once, priority delivery, and access to senior-level designers, this package enables businesses to manage multiple complex projects efficiently — from high-end branding and 3D visuals to custom illustrations and advanced product design.
Harnil Oza, CEO of Hyperlink InfoSystem, stated, "With Design Limitless, we're offering more than design - we're offering creative peace of mind. Businesses no longer need to worry about sourcing quality designers or missing deadlines. Our team becomes an extension of theirs, delivering consistent, high-impact creative work that aligns with their goals, timelines, and brand identity."
Operating through a centralized dashboard with unlimited requests and revisions, Design Limitless is designed to simplify collaboration while maintaining creative excellence. Each subscription is backed by Hyperlink InfoSystem's decade-long experience and trusted delivery process, ensuring that every brand - no matter its size - gets access to world-class design support. To explore services, view the portfolio, or subscribe to a creative plan, visit www.designlimitless.com or contact info@designlimitless.com.
About Hyperlink InfoSystem:
Hyperlink InfoSystem is a prominent international enterprise excelling in IT solutions in many domains. Since its humble beginnings in 2011, its specialization in technologies has expanded across web development, mobile app development, enterprise software solutions, and now Artificial Intelligence (AI). With over 1200+ employees and a global presence in the USA, UK, UAE, France, India, and Canada, Hyperlink InfoSystem is dedicated to assisting corporations to leverage the complete power of technology to accomplish their goals.
Contact Details:Hyperlink InfoSystemHarnil Oza+1-309-791-4105info@hyperlinkinfosystem.comNew York Address:One World Trade Center285 Fulton Street suite 8500,New York, NY 10007,United StatesAhmedabad Address:C-308, Ganesh Meridian,Opp Kargil Petrol Pump, S.G. Highway,Sola, Ahmedabad, 380061IndiaLondon Address:Level 30, The Leadenhall Building,122 Leadenhall Street,London EC3V 4ABCanada Address:151 Yonge Street, 11th Floor,Toronto, Ontario, M5C 2W7,Canada
Logo: https://mma.prnewswire.com/media/2429933/5421426/Hyperlink_InfoSystem_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/design-limitless-by-hyperlink-infosystem-becomes-a-one-stop-creative-partner-for-branding-uiux-motion-graphics--more-302524240.html
SOURCE Hyperlink InfoSystem
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Are Wall Street Analysts Bullish on Nasdaq Stock?
New York-based Nasdaq, Inc. (NDAQ) operates as a leading provider of trading, clearing, marketplace technology, securities listing, information, and other services. With a market cap of $55.6 billion, Nasdaq operates through Capital Access Platforms, Financial Technology, and Market Services segments. The company has significantly outperformed the broader market over the past year. NDAQ stock has soared 42.3% over the past 52 weeks and 25.3% on a YTD basis, compared to the S&P 500 Index's ($SPX) 20.1% surge over the past year and 8.6% returns on a YTD basis. More News from Barchart 'It Will Be the Biggest Product Ever': Elon Musk Says Tesla's Optimus Robots Will Be Bigger Than Even Robotaxi Dear Archer Aviation Stock Fans, Mark Your Calendars for August 11 Dear Plug Power Stock Fans, Mark Your Calendars for August 11 Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! Narrowing the focus, Nasdaq has also outperformed the Financial Select Sector SPDR Fund's (XLF) 22.8% gains over the past year and 7.3% returns on a YTD basis. Nasdaq's stock prices surged 5.9% in the trading session following the release of its impressive Q2 results on Jul. 24. Driven by solid organic growth, the company's revenues net of transaction expenses surged 12.7% year-over-year to $1.3 billion, beating the consensus estimates by a notable margin. Furthermore, driven by continued improvement in margins, its non-GAAP net earnings for the quarter grew 23.9% year-over-year to $492 million, and adjusted EPS of $0.85, surpassed the Street's expectations by 6.3%. For the full fiscal 2025, ending in December, analysts expect NDAQ to deliver an adjusted EPS of $3.30, up 17% year-over-year. The company has a solid earnings surprise history. It has surpassed the Street's bottom-line estimates in each of the past four quarters. The stock has a consensus 'Strong Buy' rating overall. Of the 20 analysts covering the stock, opinions include 13 'Strong Buys,' three 'Moderate Buys,' and four 'Holds.' This configuration is slightly more optimistic than a month ago, when 12 analysts gave 'Strong Buy' recommendations and the stock had a consensus 'Moderate Buy' rating overall. On Aug. 4, Piper Sandler analyst Richard Repetto maintained an 'Overweight' rating and raised the price target from $97 to $104. NDAQ's mean price target of $103.17 represents a 6.5% premium to current price levels. Meanwhile, the street-high target of $115 suggests a notable upside potential of 18.7%. On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
4 minutes ago
- Yahoo
KKR Stock: Analyst Estimates & Ratings
New York-based KKR & Co. Inc. (KKR) manages investments such as private equity, energy, infrastructure, real estate, credit strategies, and hedge funds. With a market cap of $127.1 billion, KKR specializes in acquisitions, LBOs, MBOs, credit funding, growth equity, mezzanine, distressed, turnaround, and other investments. The financial sector giant has outperformed the broader market over the past year. KKR stock prices have soared 26.5% over the past 52 weeks, outpacing the S&P 500 Index's ($SPX) 20.1% gains during the same time frame. However, in 2025, KKR is down 3.5%, lagging behind SPX's 8.6% uptick on a YTD basis. More News from Barchart 'It Will Be the Biggest Product Ever': Elon Musk Says Tesla's Optimus Robots Will Be Bigger Than Even Robotaxi Dear Archer Aviation Stock Fans, Mark Your Calendars for August 11 Dear Plug Power Stock Fans, Mark Your Calendars for August 11 Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! Narrowing the focus, KKR has also outpaced the Invesco Global Listed Private Equity ETF's (PSP) 17.7% gains over the past year, but underperformed PSP's 6.4% returns in 2025. Despite delivering better-than-expected results, KKR's stock prices dropped 2.6% following the release of its Q2 results on Jul. 31. The company reported a solid 17.6% year-over-year surge in overall revenues to $1.8 billion, beating Street estimates. Furthermore, the company's adjusted EPS for the quarter increased 8.3% year-over-year to $1.18, surpassing the consensus estimates by 3.5%. However, the company's fundraising momentum has observed several hiccups recently. On an LTM basis, at the end of Q2, KKR had raised $109 billion in new capital, marking a marginal 93 bps increase year-over-year. Meanwhile, capital raised for credit & liquid strategies dropped by 19% to $51 billion, and the figure for real assets declined by 14.7% to $29 billion; this likely unsettled investor confidence. For the full fiscal 2025, ending in December, analysts expect KKR to deliver an adjusted EPS of $5.14, up 9.4% year-over-year. Furthermore, the company has a solid earnings surprise history. It has surpassed the Street's bottom-line estimates in each of the past four quarters. The stock maintains a consensus 'Strong Buy' rating overall. Of the 19 analysts covering the stock, opinions include 15 'Strong Buys,' two 'Moderate Buys,' and two 'Holds.' This configuration is slightly less optimistic than a month ago, when 16 analysts gave 'Strong Buy' recommendations. On Aug. 4, Keefe, Bruyette & Woods analyst Kyle Voigt maintained an 'Outperform' rating on KKR and raised the price target from $155 to $162. KKR's mean price target of $162.50 represents a premium of 13.9% to current price levels. Meanwhile, the street-high target of $187 suggests a notable upside potential of 31.1%. On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 minutes ago
- Yahoo
GSK climbs after winning FDA priority review for oral gonorrhoea antibiotic
-- GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review application for gepotidacin, an oral antibiotic aimed at treating sexually transmitted uncomplicated gonorrhoea. The drugmaker's shares climbed 1% in London on the news. The company is looking to new infectious disease products, including its recently launched respiratory syncytial virus vaccine, to offset expected revenue declines from top-selling medicines and looming patent expirations in its HIV portfolio. Gepotidacin is already approved in the U.S. under the brand name Blujepa for treating a common urinary tract infection in women and adolescent girls. The FDA is expected to decide in December on its use for uncomplicated urogenital gonorrhoea, which could offer patients an oral alternative to existing injectable treatments. Separately, GSK and Germany's CureVac last week resolved a long-running patent dispute with Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) over mRNA vaccine technology used during the COVID-19 pandemic. The settlement follows BioNTech's June agreement to acquire CureVac in an all-stock deal worth $1.25 billion to advance work on mRNA-based cancer therapies. Under the settlement, CureVac and GSK will receive $740 million and single-digit percentage royalties on future U.S. sales of COVID-19 vaccines, CureVac said. GSK's share amounts to $370 million, including $50 million to adjust terms from a 2024 licence agreement that expanded their pandemic-era partnership. If BioNTech's takeover of CureVac is completed, related mRNA litigation outside the U.S. will also be resolved, with GSK receiving an additional $130 million and royalties extended to non-U.S. sales. CureVac said the acquisition remains on track under the agreed terms. GSK said it still has separate patent cases against Pfizer and BioNTech in the U.S. and Europe, which are unaffected by this settlement. Related articles GSK climbs after winning FDA priority review for oral gonorrhoea antibiotic USPS blocks major vape distributor over unregulated product shipments - Reuters Exclusive: Opendoor CEO Wheeler breaks silence, EMJ's Eric Jackson calls for more Sign in to access your portfolio
